|
HS Code |
245801 |
| Chemical Formula | C7H9NO2S |
| Molar Mass | 171.217 g/mol |
| Appearance | Solid (usually) |
| Physical State At Room Temp | Solid |
| Solubility In Water | Poor (estimated, due to hydrophobic groups) |
As an accredited 4-(1-Methylethyl)-2-Thiazolecarboxylicacid factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 500g of 4-(1 - Methylethyl)-2 - Thiazolecarboxylic acid in sealed, labeled chemical - grade containers. |
| Shipping | 4-(1 - Methylethyl)-2-Thiazolecarboxylic acid is shipped in containers designed to prevent leakage. Chemical - resistant packaging ensures safe transport, following strict regulations for handling and shipping of such substances. |
| Storage | Store 4-(1 - Methylethyl)-2 - Thiazolecarboxylic acid in a cool, dry place away from heat sources and direct sunlight. Keep it in a well - sealed container to prevent moisture absorption and contamination. Avoid storing it near reactive substances. If possible, store it in a dedicated chemical storage area following safety regulations for organic acids. |
|
Reductive amination sequences followed by amide coupling with 4-(1-methylethyl)-2-thiazolecarboxylic acid (IPTCA) represent a convergent strategy for assembling GPR40/FFA1 agonists that have progressed into Phase II clinical assessment for Type 2 diabetes. The free carboxylic acid is the primary pharmacophore anchoring point; its steric environment—the isopropyl group occupying the thiazole 4-position—attenuates PPARγ transactivation while preserving picomolar agonist potency at the GPR40 receptor. Process-scale manufacture of IPTCA-derived clinical candidates is governed by ICH Q7 Section 5.1.2 for starting material validation, with residual palladium limits set below 10 μg/g per FDA 21 CFR 211.160(b) in-process controls. In a representative convergent batch record, IPTCA is charged at 1.05-1.15 eq. relative to the amine fragment; an equimolar pre-activation with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl) and 1-hydroxybenzotriazole (HOBt) in anhydrous N,N-dimethylformamide at -5 to 0 °C suppresses the competing N-acylurea rearrangement and limits epimerization of the acid-labile prosthetic group on the eastern fragment. The coupling mass is quenched into 2 M hydrochloric acid at 0-5 °C, extracted with 2-methyltetrahydrofuran, and concentrated under reduced pressure with a jacket setpoint not exceeding 30 °C. Final recrystallization from isopropanol/water (72:28 v/v) yields the GPR40 agonist free acid with chemical purity exceeding 99.7 area% by HPLC (Inertsil ODS-3, 5 μm, 250 × 4.6 mm; mobile phase: 0.1% trifluoroacetic acid in acetonitrile/water gradient). The finished dosage form is an immediate-release tablet manufactured via roller compaction to circumvent moisture-induced dihydrate formation; tensile strength is held at 1.8-2.4 MPa per USP ⟨1062⟩. A comparative matrix of coupling reagents and their impact on epimerized byproduct formation at pilot scale (50 L reactor) is presented below.
What Limits the Coupling Yield in IPTCA-Derived FabH Inhibitor Libraries?β-Ketoacyl-acyl carrier protein synthase III (FabH) is a conserved bacterial target for methicillin-resistant Staphylococcus aureus (MRSA) therapeutics, and IPTCA has been employed as an acid fragment in arrayed solution-phase libraries of 2-aminothiazole amides. The steric demand of the isopropyl group slows acyl transfer at the 2-amino position; this kinetic bottleneck is mitigated by conducting the amidation in N-methyl-2-pyrrolidone at a controlled water activity of less than 0.2 aw with PyBOP (1.3 eq.) and N,N-diisopropylethylamine (3.0 eq.) relative to IPTCA. Bioassay-guided fractionation post-synthesis adheres to ICH M7 for DNA-reactive impurity alert structures; a purge factor calculation demonstrates that any unreacted IPTCA (predicted purge factor > 104) falls below the threshold of toxicological concern of 1.5 μg/day. The synthesis workflow is executed on a Tecan Freedom EVO liquid handler equipped with a 96-well filtration block, where IPTCA is dispensed as a 0.25 M stock in dimethyl sulfoxide. Crude products are captured on Strata-X polymeric reverse-phase cartridges and eluted with acetonitrile containing 0.05% formic acid. Minimum inhibitory concentration (MIC) values against MRSA USA400 strain are determined in cation-adjusted Mueller-Hinton broth following CLSI M07-A11; hit compounds with MIC ≤ 2 μg/mL are transitioned into time-kill kinetics. The terminal output is a lyophilized screening hit forwarded to a pharmacology unit; no solid-state characterization is performed at this stage. Industrial-scale preparation of succinate dehydrogenase inhibitor (SDHI) fungicide active ingredients entails converting IPTCA to its corresponding acid chloride under strictly anhydrous conditions. In a 2,500 L glass-lined reactor, IPTCA (1.0 kmol) is suspended in toluene containing 0.02 eq. pyridine catalyst; thionyl chloride (1.25 eq.) is metered at a rate that keeps the internal temperature between 48 and 52 °C. Process safety calorimetry (Mettler Toledo RC1, phi-factor 1.08) recorded a specific heat release of −210 kJ/kg and a maximum pressure rise rate of 1.2 bar/min under adiabatic conditions; the relief system is sized per DIERS methodology for a 2-phase vapor-liquid runaway scenario. The generated acid chloride is immediately coupled with a substituted aniline bearing a difluoromethyl moiety in the same solvent train without isolation; post-reaction, the organic layer is washed with 5% aqueous sodium bicarbonate and the amide product crystallizes upon cooling to −10 °C (crystal size d50 controlled at 8-12 μm via wet milling). The resulting technical-grade active ingredient is formulated as a 500 g/L aqueous suspension concentrate (SC) by bead milling with an EO/PO block copolymer dispersant and a xanthan gum rheology modifier, yielding a particle size below 2 μm (d90) measured by laser diffraction on a Malvern Mastersizer 3000. Finished product specifications align with the compliance matrix summarized below.
Copper(I) Iodide Complexes of IPTCA-Derived Triazolylamine Ligands in Alkyne-Azide Click ChemistryIPTCA can be converted to a 2-(4-isopropylthiazol-2-yl)-1,2,3-triazole bidentate ligand via CuAAC reaction with propargylamine, providing a nitrogen-rich coordination sphere that stabilizes Cu(I) against oxidation in aqueous media. The catalyst system, prepared freshly by stirring the ligand (0.5 mol% relative to alkyne) with copper(I) iodide in acetonitrile at 25 °C for 30 min, accelerates the cycloaddition of biomolecule-bearing azides to strained alkynes without requiring a sacrificial reductant. The ligand-to-copper stoichiometry is maintained at 1.05:1.00; excess ligand shifts turnover frequency (TOF) downward through competitive binding to the vacant Cu(I) coordination site required for alkyne π-activation. Laboratory-scale preparation for bioconjugation is conducted under ISO 13485:2016 quality management when the adduct is destined for diagnostic kit assembly. The final product is a filtered solution of the active catalyst that is used directly in the conjugation step; no isolated material is stored. In a standard immunoglobulin G modification, 3 azide groups per antibody were introduced, and the IPTCA-ligated copper catalyst achieved quantitative conversion within 45 min as assessed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. When IPTCA-Replaced Cysteine Fragments Are Introduced into Peptide Backbone Mimics for HCV NS3/4A ProteaseThiazole-containing peptide isosteres reduce susceptibility to proteolytic cleavage while maintaining the hydrogen-bonding network critical for inhibition of the hepatitis C virus NS3/4A serine protease. Fmoc-IPTCA-OH, prepared by ester hydrolysis of the corresponding ethyl ester under lithium hydroxide in tetrahydrofuran/water (3:1 v/v), is deployed as a non-natural amino acid surrogate on Rink amide AM resin (loading 0.38-0.42 mmol/g). The steric profile of the 4-isopropyl substituent necessitates a triple-coupling protocol: 3 eq. Fmoc-IPTCA-OH is activated with HATU (2.9 eq.) and 2,4,6-trimethylpyridine (6 eq.) in dimethylformamide; each coupling cycle is held for 15 min at 70 °C on a Liberty Blue microwave peptide synthesizer with instrument-calculated power typically below 35 W. Following global deprotection with trifluoroacetic acid/triisopropylsilane/water (95:2.5:2.5 v/v/v), the crude peptide is precipitated in chilled diethyl ether and dried under nitrogen. Purification by preparative reversed-phase HPLC (C18, 10 μm, 5 × 25 cm column) using a gradient of acetonitrile in 0.1% aqueous formic acid yields the IPTCA-containing macrocycle at > 96% purity. Pharmacopeial compliance is benchmarked against USP ⟨1503⟩ and ICH Q6B; counterion content (trifluoroacetate) is controlled below 0.8% w/w as measured by ion chromatography. The final dosage form is a sterile lyophilized cake reconstituted prior to intravenous administration, with residual moisture determined by Karl Fischer coulometry at ≤ 1.5%. In non-halogen flame retardant epoxy formulations for copper-clad laminate production, IPTCA has been evaluated as a latent accelerator for dicyandiamide-cure systems at loadings of 0.5-1.5 phr. The lone pair on the thiazole nitrogen reversibly complexes the dicyandiamide nitrile group, shifting the cure exotherm peak to 168-172 °C (measured by differential scanning calorimetry at 10 K/min) and extending the prepreg gel time at 140 °C beyond 420 s. Compliance with IEC 61249-2-21 defines halogen-free requirements; the finished 4-layer laminate is processed via vacuum lamination at 175 °C under 3.5 MPa consolidation pressure for 90 min and subsequently subjected to solder float testing at 288 °C for 30 s per IPC-TM-650 Method 2.4.13. |
Competitive 4-(1-Methylethyl)-2-Thiazolecarboxylicacid prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
| Property | 4-(1-Methylethyl)-2-TCA | 4-Methyl-2-TCA | 5-Isopropyl-2-TCA | 2-Thiazolecarboxylic acid |
|---|---|---|---|---|
| Melting range (DSC onset, ASTM E794, 10 K·min⁻¹) | 122–124 °C | 140–142 °C | 98–101 °C | 80–82 °C |
| pKa (capillary electrophoresis, 25 °C, I = 0.15 M NaCl) | 3.31 ± 0.03 | 3.22 ± 0.03 | 3.10 ± 0.04 | 2.85 ± 0.02 |
| Calculated log D7.4 (ACD/Labs Percepta) | −0.72 | −1.45 | −0.65 | −1.90 |
| Relative amidation rate with benzylamine (CDI, THF, 0 °C) | 0.78 | 1.00 | 0.91 | 1.32 |
| Typical residual Pd after Suzuki coupling on 5-bromo precursor | ≤ 15 ppm | ≤ 20 ppm | N/A | N/A |
| Standard | Method / Clause | Value |
|---|---|---|
| Purity (area%) | USP <621>, HPLC | ≥ 98.5% |
| Water content | USP <921>, Karl Fischer coulometry | ≤ 0.5% |
| Residue on ignition | USP <281> | ≤ 0.1% |
| Heavy metals (as Pb) | USP <231>, Method II | ≤ 20 ppm |
| Residual solvents | USP <467>, Procedure A | Class 2 solvents ≤ Option 2 limits |
| Appearance | Visual, USP <630> | White crystalline powder |